Breakthroughs in cancer research to be presented at ASCO
June 1, 2016 | by Denise Heady
Every year, thousands of physicians and researchers convene in Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting to study and share news about the latest scientific research on cancer treatment, detection and prevention.
“The annual meeting renews City of Hope’s commitment to finding the most effective cancer treatments so we can achieve a meaningful, tangible impact against the disease,” said Steven T. Rosen, M.D., provost and chief scientific officer at City of Hope. “The cancer death rate has declined in the last 50 years — due in large part to early cancer detection, more prevention efforts and better treatments — but more work remains to be done.”
Members of City of Hope’s medical oncology team are part of a core group of medical professionals trying to find more ways to treat and eradicate cancer. At the 2016 meeting, they will share findings about a number of cancers and treatment approaches, including assessments of potential new therapies and comparisons of current therapies.
Harnessing the power of the human immune system to create more powerful and less toxic cures for cancer will be a hot topic at the conference.
“Immunotherapy agents have opened a lot of doors for patients, and they are generally well-tolerated,” said Robert Chen, M.D., assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, “They hold a lot of promise.”
City of Hope researchers have found encouraging responses in a number of clinical trials and studies that will be shared at the annual meeting, June 3 to 7.
Significant City of Hope presentations at this year’s meeting include:
- Preliminary results of a phase I/II study supporting use of ixazomib, pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. Read more.
- Pembrolizumab for patients with relapsed/refractory classical Hodgkin lymphoma. Read more.
- Biomarker is linked to survival and treatment response for BRCA-positive breast cancer patients. Read more.
- New and emerging targets for advanced bladder cancers: BGJ398. Read more.
- Veliparib used in combination with chemotherapy and radiation for patients with unresectable Stage 3 nonsmall cell lung cancer. Read more.
If you are looking for a second opinion or consultation about your treatment, request an appointment online or contact us at 800-826-HOPE. Please visit Making Your First Appointment for more information.
You may also be interested in